110 related articles for article (PubMed ID: 29729562)
21. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC).
Heinemann V; Stintzing S; Modest DP; Giessen-Jung C; Michl M; Mansmann UR
Eur J Cancer; 2015 Sep; 51(14):1927-36. PubMed ID: 26188850
[TBL] [Abstract][Full Text] [Related]
22. Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.
Marandino L; La Salvia A; Sonetto C; De Luca E; Pignataro D; Zichi C; Di Stefano RF; Ghisoni E; Lombardi P; Mariniello A; Reale ML; Trevisi E; Leone G; Muratori L; Marcato M; Bironzo P; Novello S; Aglietta M; Scagliotti GV; Perrone F; Di Maio M
Ann Oncol; 2018 Dec; 29(12):2288-2295. PubMed ID: 30304498
[TBL] [Abstract][Full Text] [Related]
23. Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies.
Vogel A; Hofheinz RD; Kubicka S; Arnold D
Cancer Treat Rev; 2017 Sep; 59():54-60. PubMed ID: 28738235
[TBL] [Abstract][Full Text] [Related]
24. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.
Ter Veer E; van Rijssen LB; Besselink MG; Mali RMA; Berlin JD; Boeck S; Bonnetain F; Chau I; Conroy T; Van Cutsem E; Deplanque G; Friess H; Glimelius B; Goldstein D; Herrmann R; Labianca R; Van Laethem JL; Macarulla T; van der Meer JHM; Neoptolemos JP; Okusaka T; O'Reilly EM; Pelzer U; Philip PA; van der Poel MJ; Reni M; Scheithauer W; Siveke JT; Verslype C; Busch OR; Wilmink JW; van Oijen MGH; van Laarhoven HWM
Lancet Oncol; 2018 Mar; 19(3):e151-e160. PubMed ID: 29508762
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life assessment in contemporary phase III trials in advanced colorectal cancer.
Adamowicz K; Saad ED; Jassem J
Cancer Treat Rev; 2016 Nov; 50():194-199. PubMed ID: 27718458
[TBL] [Abstract][Full Text] [Related]
26. Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
Machida N; Yoshino T; Boku N; Hironaka S; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Asaka M
Jpn J Clin Oncol; 2008 Oct; 38(10):689-94. PubMed ID: 18845522
[TBL] [Abstract][Full Text] [Related]
27. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
28. Comparable survival outcome of metastatic colorectal cancer in Indigenous and non-Indigenous patients: Retrospective analysis of the South Australian metastatic colorectal cancer registry.
Tomita Y; Karapetis CS; Roder D; Beeke C; Hocking C; Roy AC; Townsend AR; Padbury R; Maddern G; Price TJ
Aust J Rural Health; 2016 Apr; 24(2):85-91. PubMed ID: 26255652
[TBL] [Abstract][Full Text] [Related]
29. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients.
Caballero-Baños M; Benitez-Ribas D; Tabera J; Varea S; Vilana R; Bianchi L; Ayuso JR; Pagés M; Carrera G; Cuatrecasas M; Martin-Richard M; Cid J; Lozano M; Castells A; García-Albéniz X; Maurel J; Vilella R
Eur J Cancer; 2016 Sep; 64():167-74. PubMed ID: 27428073
[TBL] [Abstract][Full Text] [Related]
30. Primary tumor location as a prognostic factor in metastatic colorectal cancer.
Loupakis F; Yang D; Yau L; Feng S; Cremolini C; Zhang W; Maus MK; Antoniotti C; Langer C; Scherer SJ; Müller T; Hurwitz HI; Saltz L; Falcone A; Lenz HJ
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25713148
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States.
Shankaran V; Ortendahl JD; Purdum AG; Bolinder B; Anene AM; Sun GH; Bentley TGK
Am J Clin Oncol; 2018 Jan; 41(1):65-72. PubMed ID: 26398184
[TBL] [Abstract][Full Text] [Related]
32. Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer.
Cirocchi R; Trastulli S; Abraha I; Vettoretto N; Boselli C; Montedori A; Parisi A; Noya G; Platell C
Cochrane Database Syst Rev; 2012 Aug; (8):CD008997. PubMed ID: 22895981
[TBL] [Abstract][Full Text] [Related]
33. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4.
Crosara Teixeira M; Marques DF; Ferrari AC; Alves MF; Alex AK; Sabbaga J; Hoff PM; Riechelmann RP
Clin Colorectal Cancer; 2015 Mar; 14(1):52-7. PubMed ID: 25442812
[TBL] [Abstract][Full Text] [Related]
34. The use and reporting of patient-reported outcomes in phase III breast cancer trials.
Brim RL; Pearson SD
Clin Trials; 2013 Apr; 10(2):243-9. PubMed ID: 23539108
[TBL] [Abstract][Full Text] [Related]
35. Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer.
Mekenkamp LJ; Heesterbeek KJ; Koopman M; Tol J; Teerenstra S; Venderbosch S; Punt CJ; Nagtegaal ID
Eur J Cancer; 2012 Mar; 48(4):501-9. PubMed ID: 22226571
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.
Feliu J; Díez de Corcuera I; Manzano JL; Valladares-Ayerbes M; Alcaide J; García García T; Vera R; Sastre J
Clin Transl Oncol; 2017 Apr; 19(4):498-507. PubMed ID: 27718155
[TBL] [Abstract][Full Text] [Related]
37. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Simkens LH; van Tinteren H; May A; ten Tije AJ; Creemers GJ; Loosveld OJ; de Jongh FE; Erdkamp FL; Erjavec Z; van der Torren AM; Tol J; Braun HJ; Nieboer P; van der Hoeven JJ; Haasjes JG; Jansen RL; Wals J; Cats A; Derleyn VA; Honkoop AH; Mol L; Punt CJ; Koopman M
Lancet; 2015 May; 385(9980):1843-52. PubMed ID: 25862517
[TBL] [Abstract][Full Text] [Related]
38. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
39. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer.
Cirocchi R; Trastulli S; Boselli C; Montedori A; Cavaliere D; Parisi A; Noya G; Abraha I
Cochrane Database Syst Rev; 2012 Jun; (6):CD006317. PubMed ID: 22696357
[TBL] [Abstract][Full Text] [Related]
40. Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxaliplatin-fluoropyrimidine doublet.
Comella P; Casaretti R; Manzo R; Sandomenico C; Licenziato M; Avallone A; Franco L;
Acta Oncol; 2010; 49(1):50-6. PubMed ID: 20100144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
